---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-026741"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:35:27.993112+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cryoport FY2021 revenue $222.6M (+183% YoY); Q4 net loss $260.1M on $251.8M debt extinguishment

## Summary
- FY2021 revenue $222.6M (+183% YoY); organic revenue from Cryoport Systems & CRYOGENE +40%.
- Q4 revenue $56.4M (+17% YoY); Biopharma/Pharma revenue $46.3M (+18%).
- Net loss Q4 $260.1M incl $251.8M non-cash debt extinguishment; Adj. EBITDA $0.8M.
- Cash & short-term investments $628.8M at Dec 31, 2021; placed $402.5M 0.75% convertible notes.
- Supports record 602 clinical trials (273 Phase 2, 74 Phase 3); fire at MVE facility expected Q1 impact $4-5M.

## SEC filing metadata
- accession: 0001104659-22-026741
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465922026741/0001104659-22-026741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465922026741/tm227658d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-026741
- JSON: https://secwatch.observer/filing/0001104659-22-026741.json
- Plain text: https://secwatch.observer/filing/0001104659-22-026741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.